Sector: Healthcare | Industry: Biotechnology & Medical Research |
See Regulatory Filings on SEC |
Company Contact | |
Address: | 45 Liberty Blvd., Suite 230 MALVERN PA 19355 |
Tel: | N/A |
Website: | https://www.galeratx.com |
IR: | See website |
Key People | ||
J. Mel Sorensen President, Chief Executive Officer, Director | Christopher Degnan Chief Financial Officer, Secretary | Robert A. Beardsley Chief Operating Officer |
Jennifer Stacey Chief Legal & Compliance Officer and Secretary | Eugene Kennedy Chief Medical Officer |
Business Overview |
Galera Therapeutics, Inc. is a biopharmaceutical company focused on developing a pipeline of novel, therapeutic candidates that have the potential to transform radiotherapy in cancer. The Company's lead product candidate, avasopasem manganese (avasopasem), is a highly selective small molecule dismutase mimetic that the Company is developing for the reduction of severe oral mucositis (SOM) in patients with head and neck cancer (HNC), the reduction of esophagitis in patients with lung cancer, and the reduction of cisplatin-induced kidney damage in patients with cancer. The Company's second product candidate, rucosopasem manganese (rucosopasem), is in development to augment the anti-cancer efficacy of stereotactic body radiation therapy in patients with non-small cell lung cancer and locally advanced pancreatic cancer. Rucosopasem is an orphan drug designation and orphan medicinal product designation for the treatment of pancreatic cancer. |
Financial Overview |
For the fiscal year ended 31 December 2023, Galera Therapeutics Inc revenues was not reported. Net loss decreased 5% to $59.1M. Lower net loss reflects Research and development - Balancing va decrease of 21% to $22.4M (expense), Interest income increase from $506K to $1.6M (income), Stock-based Compensation in R&D decrease of 35% to $1.7M (expense). Basic Earnings per Share excluding Extraordinary Items increased from -$2.30 to -$1.33. |
Employees: | 7 as of Mar 26, 2024 |
Reporting Currency: | U.S. Dollars |
Enterprise value: | $142.80M as of Dec 31, 2023 |
Annual revenue (TTM): | $0.00M as of Dec 31, 2023 |
EBITDA (TTM): | -$46.69M as of Dec 31, 2023 |
Net annual income (TTM): | -$59.08M as of Dec 31, 2023 |
Free cash flow (TTM): | -$44.91M as of Dec 31, 2023 |
Net Debt Last Fiscal Year: | $132.79M as of Dec 31, 2023 |
Shares outstanding: | 54,392,170 as of Dec 31, 2023 |
TTM: Trailing Twelve Months EBITDA: Earnings Before Interest, Taxes, Depreciation, & Amortization |